Commentary - Journal of Cellular Immunology (2021) Volume 3, Issue 3
Murine Models of Alcohol Consumption: Imperfect but Still Potential Source of Novel Biomarkers and Therapeutic Drug Discovery for Alcoholic Liver Disease
Khaled Alharshawi, Costica Aloman*
Department of Internal Medicine, Division of Digestive Diseases and Nutrition, Rush Medical College, Chicago, IL 60612, USA
- *Corresponding Author:
- Costica Aloman
Received date: March 20, 2021; Accepted date: May 17, 2021
Citation: Alharshawi K, Aloman C. Murine Models of Alcohol Consumption: Imperfect but Still Potential Source of Novel Biomarkers
and Therapeutic Drug Discovery for Alcoholic Liver Disease. J Cell Immunol. 2021; 3(3): 177-181.
Copyright: © 2021 Alharshawi K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Animal models of liver disease are fundamentally important to strengthen our knowledge and understanding of human liver diseases.
Murine models of alcohol consumption are utilized to investigate alcoholic liver injury to develop new therapeutic targets. The well
accepted and commonly used murine models of chronic alcohol consumption are Meadows-Cook (MC) and Lieber-DeCarli (LD).
LD model is based on an isocaloric high-fat liquid diet, but mice under the MC model fed on a regular chow diet with alcohol added
to the drinking water. Alcoholic liver disease in real world is frequently diagnosed in patients with obesity and high fat intake,
mirroring LD diet. The overlap of the specific effect of ethanol and obesity is difficult to differentiate by clinician and pathologist.
In this commentary, we will further discuss our research findings comparing MC and LD as a tool to dissect early alcohol versus
increased fat intake detrimental effects on the liver. The critical analysis of these two models could provide evidence to differentiate
the specific impact of alcohol on the liver from the combined influence of alcohol and diet. Ultimately, these investigations could
uncover potential biomarkers and therapeutic targets for personalized type of alcoholic liver injury.
Alcoholic liver disease (ALD); Mouse; Meadows-Cook (MC); Lieber-DeCarli (LD); Patatin-like phospholipase domain
containing 3 (Pnpla3); Lipocalin-2 (Lcn2); ELOVL Fatty Acid Elongase 6 (Elovl6); Sulfotransferase family 2A, member 3 (Sult2a3)
Improving our knowledge regarding the cellular and molecular mechanisms underlying murine models of alcoholic liver injury should enhance the management and therapies of alcoholic liver disease (ALD) seen in humans . Although none of the animal models available reproduce all main aspects of human ALD, they still provide very useful tools to study and understand the molecular mechanisms of the human counterpart . There are two well accepted and commonly used murine models of chronic alcohol consumption introduced by Meadows-Cook (MC) and Lieber-DeCarli (LD) [2,3]. In the MC model, alcohol is introduced in drinking water, in a final concentration increased gradually to reach 20% in most cases [2,4]. Mice kept in the MC model for up to 16 weeks; however, most studies use 12 weeks as the final readout point . LD was developed to enhance the alcoholic liver injury phenotype in mice [2,5]. The LD
model is based on an isocaloric liquid diet with alcohol
concentration usually increased to 3.395% for the duration
of 25 days to eight weeks, with four weeks as an average
duration used . These two murine models of chronic
alcohol consumption represent a potential investigative
tool to explore the specific effects of alcohol combined with
the high lipid liquid diet (LD) versus solid chow (MC) or
alcohol regardless of the diet type (Table 1). Our group’s
study  characterized the immune cellular, transcripts,
and histological phenotypes between LD and MC models
with encouraging results.
| Goal of the model||The simplest model developed to investigate the effect of chronic alcohol exposure on the immune system||Developed to enhance the liver injury phenotype to study the initial stages of ALD|| [2,3,5-7]|
| Model concept||Regular chow diet with alcohol added to drinking water|| High fat liquid diet with added alcohol|
|Duration average||12 weeks||4 weeks|
Table 1: Summary description of Meadows-Cook (MC) and Lieber-DeCarli (LD).
The histological phenotype in LD exposed mice with or without alcohol showed more steatosis than MC mice [2,3]. This is expected considering the liquid high fat diet in LD. This aspect of high lipid diet with alcohol (LD) which enhanced the hepatic steatosis, could represent the phenotype of alcoholic liver injury in obese people. Considering the obesity problem, at least in western societies, comparing LD and MC will help understand the molecular mechanisms of liver injury induced by alcohol alone and alcohol combined with obesity, i.e., a high fat diet.
Surprisingly, hepatic leukocytes (CD45+) are significantly higher in MC compared to LD in both alcohol-fed and control mice . Further, the majority of the hepatic leukocytes were from lymphoid lineage , contrasting with the overall enrichment in innate immune cells of pathological features of these conditions in human. There is evidence that chronic alcohol consumption decreases T cells and B cells in both humans and animal models .
Neutrophils and monocytes are critical components of ALD. Although their role is not yet clearly understood, neutrophils are important immune cells affected by alcohol, and their hepatic numbers are suggested to correlate with survival in alcoholic hepatitis [9, 10]. MC and LD models are murine models of early alcoholic liver injury and not models of alcoholic hepatitis; in these very early stages, we did not reveal significant changes in the numbers of hepatic neutrophils between alcohol-fed and control mice in both mouse models . Surprisingly, however, in both alcohol and control, the hepatic neutrophil numbers in LD mice are decreased compared to MC . Monocytes, the other counterpart innate immune cells, play an important role in ALD and potentially a cellular target for new therapeutics [11-13]. Like neutrophils, there was no difference between control and alcohol exposed mice, but mice on the MC model have higher numbers of hepatic monocytes compared to LD .
These data indicate that in the LC model, cellular immunological are somehow dimmed by high fat liquid diet and suggest that at least from a cellular immunological perspective, MC model may be potentially a closer representation of human alcoholic liver injury than the LD model. Benefiting from this, our recent study using the MC model to characterize hepatic dendritic cells (DC) revealed a gender dichotomy effect of alcohol response on hepatic plasmacytoid DCs (pDC) . Further, Using the MC diet
for four weeks, interestingly, we recently showed an earlier
increase in hepatic monocytes only in alcohol-fed female
mice compared to their control counterparts .
Furthermore, studying transcriptomics in both models unexpectedly revealed only a limited number of genes affected specifically by alcohol, diet type, or the combination .
Patatin-like phospholipase domain containing 3 (Pnpla3), a gene coding for a member of lipid hydrolase enzyme . Variants in pnpla3 gene are well known as genetic risk factors for both ALD and non-alcoholic fatty liver disease (NAFLD) [17,18]. In our study by Vogle et al. , we found that pnpla3 is the only gene that is upregulated in chronic alcohol exposed mice compared to their counterpart controls in both mouse models . However, in the absence of alcohol exposure LD diet has a different effect: pnpla3 was down regulated in LD control mice compared to MC controls . Significant for our observation in mice, in humans counterpart, suppressive mutation of pnpla3 tested in vitro and in vivo indicated a beneficial effect on NAFLD and therefore may represent a new therapeutic target for alcoholic induced steatosis [19-21].
Non-alcoholic steatohepatitis (NASH) overlap with alcoholic steatohepatitis (ASH) is difficult to differentiate in clinical practice due to the high prevalence of obesity in the general population and absence of specific pathological changes for these conditions [3,22]. Interestingly, studying differentially expressed genes in these two models hinted at potential biomarkers, which might help differentiate between NASH, ASH, and NASH-ASH combination .
Lipocalin-2 (Lcn2), also known as neutrophil gelatinaseassociated lipocalin, is expressed by tissues and immune cells in response to inflammation [23-25]. Lcn2 has been investigated in alcoholic liver injury models as well as human alcoholic hepatitis. In human alcoholic hepatitis with advanced fibrosis, Chen et al. investigated the intrahepatic Lcn2 expression and serum levels of Lcn2 . Their study showed, in alcoholic hepatitis patients, a correlation between the disease severity and portal
hypertension with increased hepatic Lcn2 expression
and Lcn2 serum levels . In LD mouse model, Lcn2
exacerbated the development of ALD, and Lcn2 knockout
protected mice from ALD and liver fibrosis [26-28]. In our
comparison, Lcn2 expression was found downregulated in
MC alcohol-fed mice compared to control and LD alcoholfed
mice . This differential regulation of Lcn2 pointing
to a potential use to differentiate ASH, represented in
the study by MC alcohol consumed, and NASH-ASH
combination, represent by LD alcohol-fed. Lcn2 was found
to be a biomarker for the coexistence of liver injury not only
induced by alcohol but when there is liver involvement in
inflammatory arthritis  or in type-2 diabetes mellitus
patients with hepatitis B co-infection .
Only a few transcripts seem to be affected by alcohol consumption in a similar way in both models and potential common target for therapies for both variants of alcoholic liver injury. ELOVL Fatty Acid Elongase 6 (Elovl6) gene codes an enzyme involved in elongating 16 carbon saturated and unsaturated fatty acids yielding 18 carbon fatty acids [31,32]. Sulfotransferase family 2A, member 3 (Sult2a3) gene express the enzymes involved in catalyzing the sulfate conjugation for many hormones and neurotransmitters . Elov6 and Sult2a3 were upregulated by alcohol consumption in MC and LD compared to controls . This upregulation, regardless of the different diets between the two mouse models, suggests the potential of using them as alcohol-specific therapeutic targets. There are no studies published so far regarding their involvement in alcoholic liver disease pathogenesis. The four genes and their potential biomarker/therapeutic utilization is described in Table 2.
|Gene||Literature||Our Finding||Biomarker/ Therapeutic target|
|Pnpla3||Variants of it are well known genetic risk factors for both ALD and NAFLD [17,18]||The only gene that is upregulated after chronic alcohol exposure in both mouse models and downregulated in LD controls compared to MC controls ||Potential common therapeutic target for alcoholic induced steatosis [19-21]|
|Lcn2||It is associated with increase in liver injury severity in mouse and human [26-28]||Downregulated in MC alcohol-fed mice compared to MC control and LD alcohol-fed mice ||Potential use to differentiate ASH from NASH-ASH combination [3,29,30]|
|Elovl6 & Sult2a3||No studies regarding their involvement in ALD pathogenesis ||Upregulated by alcohol consumption in both MC and LD compared to controls ||Potential use as target and markers of alcohol-specific the immunopathology |
Table 2: Brief description of potential biomarkers genes.
Another layer of complexity is brought by the sexbased
differential gene expression on somatic tissues, liver specifically . Pnpla3 variant was found to be a
risk factor for reduced survival of males with primary
sclerosing cholangitis . Lcn2 has shown a sex specific
difference in hepatic steatosis in a mice study . In a
diversity outbred mice study, Sult2a3 was assigned to
female liver co-regulated cluster . We do not know at
present if Elvol6 is the subject of similar modulation.
In summary, our study strongly suggests that at least in the early stages, alcohol effect on the murine liver are mechanistically quite different and model specific. Whether with increasing time of alcohol exposure, this mechanistic difference converges or remains quite distinct, highlights the importance of continuing these studies. These studies suggesting diversity of ALD needs be validated in human as well. The results of such studies might surprise us in a way that alcoholic hepatitis in a slim person may not be the same disease from a mechanistic perspective as in an obese person, and therefore, they should not be treated the same, in spite of their similar histological characteristics.
The authors declare they do not have any known financial
conflict of interest
Sources of Funding
This work was supported by the National Institutes of
Health [R01 AA024762], awarded to Dr. Costica Aloman.
KA wrote the manuscript. CA outlined and edited the manuscript and obtained the funding. The final version of the manuscript is approved by all authors.
Not applicable. The authors listed are the only contributors
to this manuscript.
- Ohashi K, Pimienta M, Seki E. Alcoholic liver disease: A
current molecular and clinical perspective. Liver Research.
- Nevzorova YA, Boyer-Diaz Z, Cubero FJ, Gracia-
Sancho J. Animal models for liver disease - A practical
approach for translational research. Journal of Hepatology.
- Vogle A, Qian T, Zhu S, Burnett E, Fey H, Zhu Z, et
al. Restricted immunological and cellular pathways are
shared by murine models of chronic alcohol consumption.
Scientific Reports. 2020;10(1):2451.
- Meyerholz DK, Edsen-Moore M, McGill J, Coleman
RA, Cook RT, Legge KL. Chronic alcohol consumption
increases the severity of murine influenza virus infections.
Journal of Immunology. 2008;181(1):641-8.
- ieber CS, DeCarli LM, Sorrell MF. Experimental
methods of ethanol administration. Hepatology.
- Brandon-Warner E, Schrum LW, Schmidt CM,
McKillop IH. Rodent models of alcoholic liver disease: of
mice and men. Alcohol. 2012;46(8):715-25.
- Lamas-Paz A, Hao F, Nelson LJ, Vazquez MT, Canals S,
Gomez Del Moral M, et al. Alcoholic liver disease: Utility
of animal models. World Journal of Gastroenterology.
- Pasala S, Barr T, Messaoudi I. Impact of Alcohol Abuse
on the Adaptive Immune System. Alcohol Research :
Current Reviews. 2015;37(2):185-97.
- Szabo G, Saha B. Alcohol’s Effect on Host Defense.
Alcohol research : Current Reviews. 2015;37(2):159-70.
- Altamirano J, Miquel R, Katoonizadeh A, Abraldes
JG, Duarte-Rojo A, Louvet A, et al. A histologic scoring
system for prognosis of patients with alcoholic hepatitis.
Gastroenterology. 2014;146(5):1231-9 e1-6.
- Ju C, Mandrekar P. Macrophages and Alcohol-Related
Liver Inflammation. Alcohol Research : Current Reviews.
- Tacke F. Targeting hepatic macrophages to treat liver
diseases. Journal of Hepatology. 2017;66(6):1300-12.
- Guillot A, Tacke F. Liver Macrophages: Old Dogmas
and New Insights. Hepatology communications.
- Alharshawi K, Fey H, Vogle A, Klenk T, Kim M, Aloman
C. Sex specific effect of alcohol on hepatic plasmacytoid
dendritic cells. International Immunopharmacology.
- Alharshawi K, Fey H, Vogle A, Klenk T, Kim M, Aloman
C. Alcohol Consumption Accumulation of Monocyte
Derived Macrophages in Female Mice Liver Is Interferon
Alpha Receptor Dependent. Frontiers in Immunology.
- Kienesberger PC, Oberer M, Lass A, Zechner R.
Mammalian patatin domain containing proteins: a family
with diverse lipolytic activities involved in multiple
biological functions. Journal of Lipid Research. 2009;50
- Stickel F, Hampe J. Genetic determinants of alcoholic
liver disease. Gut. 2012;61(1):150-9.
- Grimaudo S, Pipitone RM, Pennisi G, Celsa C,
Camma C, Di Marco V, et al. Association Between PNPLA3
rs738409 C>G Variant and Liver-Related Outcomes in
Patients With Nonalcoholic Fatty Liver Disease. Clinical
Gastroenterology and Hepatology : The Official Clinical
Practice Journal of the American Gastroenterological
Association. 2020;18(4):935-44 e3.
- Krawczyk M, Liebe R, Lammert F. Toward
Genetic Prediction of Nonalcoholic Fatty Liver Disease
Trajectories: PNPLA3 and Beyond. Gastroenterology.
- Schwartz BE, Rajagopal V, Smith C, Cohick E,
Whissell G, Gamboa M, et al. Discovery and Targeting of
the Signaling Controls of PNPLA3 to Effectively Reduce
Transcription, Expression, and Function in Pre-Clinical
NAFLD/NASH Settings. Cells. 2020;9(10).
- Dong XC. PNPLA3-A Potential Therapeutic Target
for Personalized Treatment of Chronic Liver Disease.
Frontiers in Medicine. 2019;6:304.
- Horvath B, Allende D, Xie H, Guirguis J, Jeung J,
Lapinski J, et al. Interobserver Variability in Scoring
Liver Biopsies with a Diagnosis of Alcoholic Hepatitis.
Alcoholism, Clinical and Experimental Research.
- Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N.
Isolation and primary structure of NGAL, a novel protein
associated with human neutrophil gelatinase. The Journal
of Biological Chemistry. 1993;268(14):10425-32.
- Chan P, Simon-Chazottes D, Mattei MG, Guenet
JL, Salier JP. Comparative mapping of lipocalin genes
in human and mouse: the four genes for complement C8
gamma chain, prostaglandin-D-synthase, oncogene-24p3,
and progestagen-associated endometrial protein map to
HSA9 and MMU2. Genomics. 1994;23(1):145-50.
- Cowland JB, Borregaard N. Molecular characterization
and pattern of tissue expression of the gene for neutrophil
gelatinase-associated lipocalin from humans. Genomics.
- Chen J, Argemi J, Odena G, Xu MJ, Cai Y, Massey V,
et al. Hepatic lipocalin 2 promotes liver fibrosis and portal
hypertension. Scientific Reports. 2020;10(1):15558.
- Wieser V, Tymoszuk P, Adolph TE, Grander C,
Grabherr F, Enrich B, et al. Lipocalin 2 drives neutrophilic
inflammation in alcoholic liver disease. Journal of
- Cai Y, Jogasuria A, Yin H, Xu MJ, Hu X, Wang J, et al.
The Detrimental Role Played by Lipocalin-2 in Alcoholic
Fatty Liver in Mice. The American Journal of Pathology.
- Jia J, Yang L, Cao Z, Wang M, Ma Y, Ma X, et al.
Neutrophil-derived lipocalin-2 in adult-onset Still’s
disease: a novel biomarker of disease activity and liver
damage. Rheumatology. 2021;60(1):304-15.
- Shahnawaz W, Suhail N, Siddiqui MAI, Yasmeen S,
Fatima SS. Does Lipocalin-2 Affect Metabolic Syndrome in
Hepatic Infections? Cureus. 2020;12(8):e10040.
- Moon YA, Shah NA, Mohapatra S, Warrington JA,
Horton JD. Identification of a mammalian long chain
fatty acyl elongase regulated by sterol regulatory elementbinding
proteins. The Journal of biological chemistry.
- Matsuzaka T, Shimano H, Yahagi N, Yoshikawa
T, Amemiya-Kudo M, Hasty AH, et al. Cloning and
characterization of a mammalian fatty acyl-CoA elongase
as a lipogenic enzyme regulated by SREBPs. Journal of
Lipid Research. 2002;43(6):911-20.
- Weinshilboum RM, Otterness DM, Aksoy IA, Wood
TC, Her C, Raftogianis RB. Sulfation and sulfotransferases
1: Sulfotransferase molecular biology: cDNAs and genes.
FASEB journal : official publication of the Federation of
American Societies for Experimental Biology. 1997;11(1):3-
- Melia T, Waxman DJ. Genetic factors contributing
to extensive variability of sex-specific hepatic gene
expression in Diversity Outbred mice. PLoS One.
- Friedrich K, Rupp C, Hov JR, Steinebrunner N, Weiss
KH, Stiehl A, et al. A frequent PNPLA3 variant is a sex
specific disease modifier in PSC patients with bile duct
stenosis. PLoS One. 2013;8(3):e58734.
- Chella Krishnan K, Sabir S, Shum M, Meng Y, Acin-
Perez R, Lang JM, et al. Sex-specific metabolic functions of
adipose Lipocalin-2. Molecular Metabolism. 2019;30:30-